The short version: the evidence points to a tight 6-7 day onset window for vaccine-triggered ITP, but it comes from a single case report, not a population study.
The only direct evidence matching your question is a 2016 case report in Pediatrics . A 4.5-year-old boy had three separate episodes of immune thrombocytopenia, each landing 6 to 7 days after his annual flu shot. The pattern was clean: symptoms appeared within a week of vaccination, he recovered fully between episodes, and when he skipped the shot one fall, no ITP occurred. The authors used the WHO-UMC causality system and rated the association "certain" . A separate case report from 2013 describes Evans' syndrome (autoimmune destruction of both red cells and platelets) after influenza vaccine, but it does not specify the onset timing .
That is the entire evidence base. One child, three recurrences, a consistent window. No large observational study has tracked onset timing in a cohort of vaccine-associated ITP cases. No manufacturer-funded trial has reported this endpoint. The literature on influenza vaccine immunology in the retrieved evidence is about antibody responses, T cell activation, and adjuvant effects in mice, elderly patients, and transplant recipients. None of it addresses ITP timing. The gap matters: a single case report establishes a plausible mechanism and a tight temporal signature, but it cannot tell you the incidence rate or whether the window varies by age, vaccine brand, or prior history.
| Evidence | Onset window | Population | Strength |
|---|---|---|---|
| Case report | 6-7 days post-vaccination | Single child, 3 recurrences | High for timing, low for generalizability |
| Evans' syndrome case | Not specified | Single adult | Does not answer the question |
My call: the appropriate onset timing for influenza vaccine-triggered ITP is 6 to 7 days post-injection, based on the only direct evidence available. Confidence: moderate for the timing claim itself, low for how well it generalizes beyond the reported case.
This page answers the follow-up:
Question explored with the scientific record
Based on a biologically plausible mechanism, what is the appropriate timing?
The short version: the evidence retrieved does not contain a single study that answers your question about onset timing for vaccine-triggered ITP.
The evidence block you provided covers COVID-19 vaccine adverse events in Indian healthcare workers [1], avian influenza glycosylation [2], measles T-cell epitopes [3], trypanosome B-cell maintenance [4], VITT case counts [5], a Brucella proteome [6], an influenza HI assay protocol [7], cytokine adjuvants in mice [8], TB lipoproteins [9], live influenza neuraminidase in mice [10], and two papers on a human monoclonal anti-platelet autoantibody from 1992 [11, 12]. None of these studies report onset timing for ITP after any vaccine. The VITT paper [5] describes thrombocytopenia with thrombosis after ChAdOx1, but it gives case counts and mortality rates, not a day-by-day onset window for isolated ITP.
The 1992 papers [11, 12] are the closest to your mechanism: they show that healthy humans carry B cells capable of making anti-platelet GPIIb/IIIa autoantibodies. That supports the biological plausibility that a vaccine could trigger those clones. But the papers do not measure onset timing, vaccine exposure, or clinical ITP. They prove the potential exists, not when it activates.
The evidence retrieved does not address this specific question. The gap itself matters: no study in this set tracked the interval between vaccination and ITP diagnosis. Without that data, the appropriate timing cannot be determined from these records.
My call: the evidence retrieved does not answer the question. Confidence: not clear.
Sources examined 13
-
Adverse events associated with COVID-19 vaccination among health care professionals of Himachal Pradesh- a Rapid Survey.
In a cross-sectional survey of 187 health care professionals in Himachal Pradesh, COVID-19 vaccination with Covishield produced mostly mild adverse events, no severe reactions, and frequencies similar to or lower than other common vaccines.
DOI: 10.47203/ijch.2021.v33i03.023 -
Addition of N-glycosylation sites on the globular head of the H5 hemagglutinin induces the escape of highly pathogenic avian influenza A H5N1 viruses from vaccine-induced immunity
This study investigates how the addition of N-glycosylation sites on the hemagglutinin of H5N1 avian influenza viruses can induce escape from vaccine-induced immunity, demonstrating that a single additional glycosite significantly contributes to this immune evasion.
DOI: 10.1016/j.virol.2015.08.033 -
Impact of genotypic variability of measles virus T-cell epitopes on vaccine-induced T-cell immunity
This study investigates the impact of genotypic variability of measles virus T-cell epitopes on vaccine-induced T-cell immunity, revealing that mutations in epitope regions can significantly impair the effectiveness of vaccine-induced CD4+ T-cell responses.
DOI: 10.1038/s41541-025-01088-y -
Maintenance of B cells during chronic murine Trypanosoma brucei gambiense infection
This study investigates the maintenance of follicular B cells during chronic murine Trypanosoma brucei gambiense infection, revealing that lower levels of inflammation correlate with the retention of these cells and the preservation of vaccine-induced immune responses against un…
DOI: 10.1111/pim.12344 -
A new enemy is emerging in the fight against the SARS-CoV-2 pandemic
This study investigates vaccine-induced immune thrombotic thrombocytopenia (VITT) following the ChAdOx1 nCoV-19 vaccination, highlighting its clinical features, pathogenesis, and implications for vaccine administration in different age groups.
DOI: 10.3324/haematol.2021.279186 -
A comprehensive proteogenomic study of the human Brucella vaccine strain 104 M
This study employs a proteogenomic approach to analyze the whole proteome and refine the genome annotation of the Brucella abortus vaccine strain 104 M, identifying 1,729 proteins and confirming 14 virulence factors and 17 protective antigens, thereby enhancing understanding of …
DOI: 10.1186/s12864-017-3800-9 -
An Optimized Hemagglutination Inhibition (HI) Assay to Quantify Influenza-specific Antibody Titers
This study presents an optimized hemagglutination inhibition assay for quantifying influenza-specific antibody titers, demonstrating its application in assessing vaccine-induced immunity and cross-reactivity among different influenza strains.
DOI: 10.3791/55833 -
Coimmunization with IFN- gamma or IL-2, but Not IL-13 or IL-4 cDNA Can Enhance Th1-Type DNA Vaccine-Induced
This study investigates the immunomodulatory effects of coadministering cDNA for Th1-type cytokines (IFN-g and IL-2) and Th2-type cytokines (IL-4 and IL-13) as molecular adjuvants to enhance DNA vaccine-induced immune responses in mice, revealing that IFN-g significantly drives …
DOI: 10.1089/107999000312450 -
The M. tuberculosis Phosphate-Binding Lipoproteins PstS1 and PstS3 Induce Th1 and Th17 Responses That Are Not Associated with Protection against M. tuberculosis Infection
The study evaluates Mycobacterium tuberculosis phosphate-binding lipoproteins PstS1 and PstS3 as vaccine antigens using various DNA/protein prime-boost regimens with the LTK63 adjuvant in mice, finding strong Th1/Th17–biased immune responses but no protection against M. tubercul…
DOI: 10.1155/2011/690328 -
Comparative immunogenicity of live influenza viruses and their solubilized neuraminidases: Results of mouse protection experiments
This study investigates the immunogenicity and protective efficacy of live influenza virus strains and their solubilized neuraminidases in mice, demonstrating that live virus vaccination induces stronger immunity compared to subunit vaccines.
DOI: 10.1007/BF01315002 -
A human monoclonal autoantibody to platelet glycoprotein IIb derived from normal human lymphocytes
Normal human tonsillar lymphocytes can generate monoclonal autoantibodies against platelet GPIIb/IIIa; STO 171, an IgM antibody derived from such cells, binds a 140 kDa platelet protein consistent with GP IIb and shows platelet-restricted reactivity with no endothelial or RBC cr…
DOI: 10.1182/blood.v79.2.447.bloodjournal792447 -
A human monoclonal autoantibody to platelet glycoprotein IIb derived from normal human lymphocytes
Normal human tonsillar lymphocytes fused with a lymphoblastoid partner can generate a monoclonal IgM autoantibody that specifically targets platelet glycoprotein IIb/IIIa, demonstrating that healthy individuals can produce antiplatelet autoantibodies.
DOI: 10.1182/blood.v79.2.447.447 -
FcγRIIa - dependent platelet activation identified in COVID-19 vaccine-induced immune thrombotic thrombocytopenia-, heparin-induced thrombocytopenia, streptokinase- and anisoylated plasminogen-streptokinase activator complex-induced platelet activation
A narrative review examining how FcγRIIa-dependent platelet activation underlies vaccine-induced immune thrombotic thrombocytopenia (VITT) and parallels heparin-induced thrombocytopenia, streptokinase, and APSAC-induced platelet disorders, using comparative analysis to better un…
DOI: 10.3389/fcvm.2023.1282637